Alec Nielsen is co-founder and CEO of Asimov, a Boston-based synthetic biology company developing a platform for computer-aided genetic engineering. Since its formation, Asimov has raised >$200M to improve the design and manufacture of therapeutics, including biologics, cell/gene therapy, and RNA. Alec holds a B.S. in Bioengineering and Electrical Engineering from the University of Washington, and a Ph.D. from MIT Biological Engineering. Alec's overarching mission is to advance humanity's ability to design living systems, enabling biotechnologies with outsized benefit to civilization.
We are developing a new way to program living cells by integrating synthetic biology, computational biology, and large AI models. We focus this platform on enabling the design and manufacture of advanced therapies.
